{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:24:50Z","timestamp":1776853490998,"version":"3.51.2"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec><jats:title>Objectives:<\/jats:title><jats:p>With the introduction of novel immune therapeutics for the treatment of disseminated malignancies, we sought to evaluate whether deliberate sequencing of immunotherapy before\/after conventional cytotoxic chemotherapy would have an impact on clinical outcomes in patients with previously treated metastatic melanoma. We sought to evaluate whether or not ipilimumab immunotherapy administered before or after cytotoxic chemotherapy (nab-paclitaxel+bevacizumab, AB) would impact clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>We conducted a randomized phase 2 clinical trial of patients with BRAF wild-type metastatic melanoma (up to 2 prior therapies) who received either: (A) AB followed by ipilimumab therapy at progression; or (B) ipilimumab followed by AB treatment at progression. The primary goal of the study was a comparison of AB versus ipilimumab progression-free survival, with secondary clinical and laboratory endpoints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>This study did not reach full accrual due to concurrent Food and Drug Administration approval of anti-programmed cell death 1 agents. Nevertheless, the available data suggests a cumulative therapeutic advantage to the sequential use of ipilimumab followed by AB. Correlative laboratory data revealed a favorable effect on systemic immune homeostasis in patients receiving AB therapy, of potential interest in further investigations, especially in the context of chemotherapy\/immunotherapy combinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Albeit limited in scope, our data suggest that cytotoxic therapy with nab-paclitaxel and bevacizumab appear to favorably alter systemic parameters of immune function of potential benefit in combination T-cell directed immune checkpoint inhibitor therapy.<\/jats:p><\/jats:sec>","DOI":"10.1097\/coc.0000000000000644","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T19:56:42Z","timestamp":1575662202000},"page":"115-121","source":"Crossref","is-referenced-by-count":22,"title":["Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Svetomir N.","family":"Markovic","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera J.","family":"Suman","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Division of Biomedical Statistics and Bioinformatics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad","family":"Javed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darci J.","family":"Wall","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori A.","family":"Erickson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic Rochester, Rochester"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ernstoff","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Metro Minnesota Community Oncology Research Consortium, St Louis Park, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejps.2009.08.009","article-title":"Paclitaxel and immune system","volume":"38","author":"Javeed","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.24720","article-title":"A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma","volume":"116","author":"Hersh","year":"2010","journal-title":"Cancer"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1093\/annonc\/mdv324","article-title":"A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma","volume":"26","author":"Hersh","year":"2015","journal-title":"Ann Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.25659","article-title":"A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1)","volume":"117","author":"Kottschade","year":"2011","journal-title":"Cancer"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.27760","article-title":"A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775","volume":"119","author":"Kottschade","year":"2013","journal-title":"Cancer"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/COC.0b013e318287bbae","article-title":"Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma","volume":"38","author":"Spitler","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"e24436","DOI":"10.4161\/onci.24436","article-title":"The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma","volume":"2","author":"Mansfield","year":"2013","journal-title":"Oncoimmunology"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/oxfordjournals.annonc.a010762","article-title":"Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha","volume":"7","author":"Legha","year":"1996","journal-title":"Ann Oncol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1200\/JCO.1998.16.5.1752","article-title":"Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma","volume":"16","author":"Legha","year":"1998","journal-title":"J Clin Oncol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","article-title":"Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group","volume":"26","author":"Atkins","year":"2008","journal-title":"J Clin Oncol"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3389\/fimmu.2018.01739","article-title":"Combining immune checkpoint inhibitors with conventional cancer therapy","volume":"9","author":"Yan","year":"2018","journal-title":"Front Immunol"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"e97828","DOI":"10.1172\/jci.insight.97828","article-title":"CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy","volume":"3","author":"Yan","year":"2018","journal-title":"JCI Insight"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T07:28:40Z","timestamp":1722151720000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000644"}},"subtitle":["Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261206I"],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000644","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,3]]}}}